Zurcher Kantonalbank Zurich Cantonalbank Trims Stock Position in DaVita Inc. (NYSE:DVA)

Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 40.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 67,524 shares of the company's stock after selling 45,176 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.09% of DaVita worth $10,329,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after acquiring an additional 76 shares during the last quarter. Copia Wealth Management purchased a new stake in DaVita during the fourth quarter valued at about $30,000. Coppell Advisory Solutions LLC grew its stake in shares of DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after buying an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan purchased a new position in DaVita in the 4th quarter worth approximately $55,000. Finally, GeoWealth Management LLC lifted its position in DaVita by 30.6% in the fourth quarter. GeoWealth Management LLC now owns 525 shares of the company's stock valued at $79,000 after purchasing an additional 123 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider directly owned 26,038 shares of the company's stock, valued at $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DVA shares. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial cut their target price on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $167.40.

DaVita Stock Down 1.4%

Shares of DVA stock traded down $1.93 during midday trading on Friday, reaching $138.44. 686,266 shares of the stock were exchanged, compared to its average volume of 672,836. The firm has a market cap of $10.45 billion, a PE ratio of 13.72, a price-to-earnings-growth ratio of 0.97 and a beta of 1.09. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1 year low of $131.76 and a 1 year high of $179.60. The company's 50 day moving average is $140.44 and its two-hundred day moving average is $148.08.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The company had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. During the same period last year, the firm earned $2.26 EPS. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.